准确瘤学:TPD在向CDK2和超越目标中的作用
1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ACS medicinal chemistry letters
|July 17, 2024
概括
向性蛋白质降解 (TPD) 通过降解癌症驱动蛋白质,如循环林依赖激酶2 (CDK2) 等,提供了新的精确瘤治疗方法. 这些TPD策略显示出破坏癌细胞生长和推进向癌症治疗的前景.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 循环素依赖激酶2 (CDK2) 是一个关键的细胞循环调节剂,与癌症进展有关.
- 异常的CDK2活性驱动瘤发生,使其成为一个重要的治疗点.
研究的目的:
- 突出针对CDK2降解的创新向蛋白质降解 (TPD) 策略.
- 探索TPD在破坏癌细胞增殖和推进精确瘤学的潜力.
主要方法:
- 审查专利文献,重点关注针对CDK的TPD技术2.
- 对癌细胞中选择性蛋白质降解的TPD机制的分析.
主要成果:
- TPD策略显示了向CDK2和其他瘤原蛋白的巨大潜力.
- 这些方法为抑制癌细胞增殖提供了一种新的治疗途径.
结论:
- TPD技术代表了精密瘤学的变革性方法.
- TPD的多功能性使其适用于各种关键癌症点,有望提供有效的疗法.
相关概念视频
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


